A Phase 3 interventional study of Telaprevir and Pegylated Interferon Alfa-2a in Hepatitis C, Chronic, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 83 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-06-10.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing telaprevir in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C, Chronic.
Among the 27 studies testing telaprevir in Hepatitis C, Chronic, this one is the 3rd largest by enrollment, is one of 4 that started in 2011, is one of 12 in phase 3, and was the 12th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 27 studies testing telaprevir in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 239 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 54 across the 27 interventional studies. Of the 25 that completed or were terminated, 16 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 27 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
11 studies in Hepatitis C, Chronic by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 11 finished, 3 (27%) have results posted.
Among the 11 studies in Hepatitis C, Chronic by Vertex Pharmaceuticals Incorporated, this one is the 3rd largest by enrollment, is the only one that started in 2011, is the only one in phase 3, and was the 6th registered.
Vertex Pharmaceuticals Incorporated’s Hepatitis C, Chronic studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing telaprevir in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Vertex Pharmaceuticals Incorporated’s 11 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate if a 12-week total regimen of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) (T12/PR12) is safe and effective in subjects who have the interleukin-28B (IL28B) CC genotype. The subjects enrolled in this study will have chronic hepatitis C virus (HCV) infection and will not have cirrhosis of the liver.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus \[HCV\] Ribonucleic Acid \[RNA\] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.
Drug: Telaprevir · Drug: Pegylated Interferon Alfa-2a · Drug: Ribavirin
Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.
Drug: Telaprevir · Drug: Pegylated Interferon Alfa-2a · Drug: Ribavirin
Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.
Drug: Telaprevir · Drug: Pegylated Interferon Alfa-2a · Drug: Ribavirin
Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.
Drug: Telaprevir · Drug: Pegylated Interferon Alfa-2a · Drug: Ribavirin
Tablet
Also known as: INCIVEK, INCIVO, VX-950
Subcutaneous Injection
Also known as: Pegasys, Peg-IFN-Alfa-2a
Tablet
Also known as: Copegus, RBV
Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
Time frame: 12 weeks after last planned dose of study drug (up to Week 36)
Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)
SVR4 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 4 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
Time frame: 4 weeks after last planned dose of study drug (up to Week 28)
Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)
SVR24 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 24 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
Time frame: 24 weeks after last planned dose of study drug (up to Week 48)
Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72)
SVR72 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 72. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
Time frame: Week 72
Percentage of Subjects With Viral Relapse
Viral relapse was defined as having detectable HCV RNA during antiviral follow-up in subjects who had HCV RNA less than (\<) lower limit of quantification (LLOQ) at end of treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The LLOQ was 25 IU/mL and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
Time frame: After last dose of study drug up to 4 weeks (up to Week 28), 12 weeks (up to Week 36), 24 weeks (up to Week 48) antiviral follow-up
Percentage of Subjects With On-Treatment Virologic Failure
On-treatment virologic failure was defined as subjects who met futility (as per investigator discretion) or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks). This outcome was planned to be assessed in all reporting groups and results were to be reported for total arm as well.
Time frame: Baseline up to Week 48
Number of Subjects With Rapid Viral Response (RVR)
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
Time frame: Week 4
Number of Subjects With Extended Rapid Viral Response (eRVR)
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
Time frame: Week 4 and Week 12
Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents administered during the course of the study.
Time frame: Baseline up to Week 48
| Milestone | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) | Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) |
|---|---|---|---|---|
| Started | 106 | 52 | 19 | 62 |
| Completed | 65 | 32 | 6 | 29 |
| Not completed | 41 | 20 | 13 | 33 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 | 5 |
| Withdrew: Lost to follow-up | 7 | 4 | 1 | 8 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Non- compliance | 0 | 0 | 0 | 3 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 30 | 15 | 9 | 11 |
| Withdrew: Other | 0 | 0 | 3 | 1 |
| Withdrew: Did not meet inclusion criteria | 0 | 0 | 0 | 1 |
SVR12 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 12 weeks after last planned dose of study drug. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
| percentage of participants | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) |
|---|---|---|
| Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12) | 88.7 | 96.2 |
SVR4 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 4 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
| percentage of participants | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) |
|---|---|---|
| Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4) | 89.6 | 98.1 |
SVR24 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at 24 weeks after last planned dose of study treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
| percentage of participants | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) |
|---|---|---|
| Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24) | 85.8 | 92.3 |
SVR72 was defined as an undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 72. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 international units per milliliter (IU/mL) and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
| percentage of participants | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) |
|---|---|---|
| Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72) | 72.4 | 86.5 |
Viral relapse was defined as having detectable HCV RNA during antiviral follow-up in subjects who had HCV RNA less than (\<) lower limit of quantification (LLOQ) at end of treatment. The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The LLOQ was 25 IU/mL and the lower limit of detection was 10 IU/mL. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
| percentage of participants | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) |
|---|---|---|
| 4 Weeks | 1.9 | 0.0 |
| 12 Weeks | 7.5 | 0.0 |
| 24 Weeks | 10.4 | 0.0 |
On-treatment virologic failure was defined as subjects who met futility (as per investigator discretion) or who completed the assigned treatment duration and had detectable HCV RNA at planned end of treatment (up to 48 weeks). This outcome was planned to be assessed in all reporting groups and results were to be reported for total arm as well.
| percentage of participants | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) | Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) | Telaprevir+Peg-IFN-alfa-2a, RBV (Total) |
|---|---|---|---|---|---|
| Percentage of Subjects With On-Treatment Virologic Failure | 0 | 0 | 0 | 3.3 | 0.8 |
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. RVR was defined as undetectable HCV RNA 4 weeks after the start of study treatment. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
| participants | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) |
|---|---|---|
| Number of Subjects With Rapid Viral Response (RVR) | 106 | 52 |
The plasma HCV RNA level was measured using Roche TaqMan HCV RNA assay. The lower limit of quantification was 25 IU/mL and the lower limit of detection was 10 IU/mL. eRVR was defined as undetectable HCV RNA at both 4 weeks and 12 weeks after the start of study treatment. This outcome was planned to be assessed only in "Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)" and "Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)" reporting groups.
| participants | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) |
|---|---|---|
| Number of Subjects With Extended Rapid Viral Response (eRVR) | 105 | 51 |
AE: any adverse change from the subject's baseline (pre-treatment) condition, including any adverse experience, abnormal recording or clinical laboratory assessment value which occurs during the course of the study, whether it is considered related to the study drug or not. An adverse event includes any newly occurring event or previous condition that has increased in severity or frequency since the administration of study drug. SAE: medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. "Study drug" includes all investigational agents administered during the course of the study.
| participants | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) | Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) |
|---|---|---|---|---|
| AEs | 104 | 51 | 19 | 61 |
| SAEs | 5 | 4 | 3 | 13 |
Collected over Baseline up to Week 48. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | — | 5/106 (4.7%) | 104/106 (98.1%) |
| Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | — | 4/52 (7.7%) | 51/52 (98.1%) |
| Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) | — | 3/19 (15.8%) | 19/19 (100%) |
| Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) | — | 13/62 (21%) | 61/62 (98.4%) |
| Event | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) | Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/106 | 3/52 | 2/19 | 7/62 |
| Abscess oralInfections and infestations | 0/106 | 0/52 | 1/19 | 0/62 |
| BacteraemiaInfections and infestations | 0/106 | 0/52 | 1/19 | 0/62 |
| PneumoniaInfections and infestations | 0/106 | 0/52 | 0/19 | 3/62 |
| PyrexiaGeneral disorders | 0/106 | 1/52 | 0/19 | 0/62 |
| Perirectal abscessInfections and infestations | 0/106 | 1/52 | 0/19 | 0/62 |
| AstheniaGeneral disorders | 0/106 | 0/52 | 0/19 | 1/62 |
| Chest painGeneral disorders | 0/106 | 0/52 | 0/19 | 1/62 |
| FatigueGeneral disorders | 0/106 | 0/52 | 0/19 | 1/62 |
| HypotensionVascular disorders | 0/106 | 0/52 | 0/19 | 1/62 |
| Event | Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) | Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 49/106 | 19/52 | 13/19 | 33/62 |
| FatigueGeneral disorders | 55/106 | 25/52 | 12/19 | 26/62 |
| AnaemiaBlood and lymphatic system disorders | 42/106 | 22/52 | 10/19 | 20/62 |
| RashSkin and subcutaneous tissue disorders | 31/106 | 15/52 | 9/19 | 13/62 |
| Influenza like illnessGeneral disorders | 28/106 | 10/52 | 8/19 | 9/62 |
| PruritusSkin and subcutaneous tissue disorders | 44/106 | 17/52 | 8/19 | 24/62 |
| DiarrhoeaGastrointestinal disorders | 19/106 | 6/52 | 6/19 | 11/62 |
| VomitingGastrointestinal disorders | 17/106 | 6/52 | 6/19 | 11/62 |
| Dry skinSkin and subcutaneous tissue disorders | 11/106 | 11/52 | 6/19 | 4/62 |
| DizzinessNervous system disorders | 17/106 | 6/52 | 6/19 | 14/62 |
Full Analysis (FA) Set included all subjects who received at least 1 dose of study drug and fulfilled all relevant inclusion criteria. One subject from "Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)" was excluded from the FA Set due to having HCV Genotype 6.
| Age, Continuous(years) | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) | Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) | Total |
|---|---|---|---|---|---|
| Mean | 46.1 ± 12.82 | 44.8 ± 12.89 | 54.4 ± 8.70 | 49.8 ± 10.56 | 47.4 ± 12.26 |
| Sex: Female, Male(Participants) | Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized) | Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized) | Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized) | Total |
|---|---|---|---|---|---|
| Female | 39 | 16 | 11 | 29 | 95 |
| Male | 67 | 36 | 8 | 32 | 143 |
The record gives a start of Nov 2011, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telaprevir · Peginterferon alfa-2a · Ribavirin
Vertex Pharmaceuticals Incorporated →